# A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

> **NCT03502681** · PHASE1 · TERMINATED · sponsor: **Monika Joshi, MD** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Urothelial Cell Cancer

## Interventions

- **DRUG:** Eribulin Mesylate
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03502681
- **Lead sponsor:** Monika Joshi, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-12
- **Primary completion:** 2019-10-25
- **Final completion:** 2019-10-25
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Funder Decision
- **Last updated:** 2022-07-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502681, "A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03502681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*